Kintor nuovo degradatore AR senza effetti collaterali
- Thread starter Lucio83
- Start date
Se non sbaglio avevano detto che vista la complessità non era possibile riprodurlo...
Ci si deve fare ibernare ai primi sintomi dell'aga ...quando troveranno la cura ti scongelano ,in ogni caso il problema è risolto sia che la trovano o meno xchè in fin dei conti non ci si pensa più (pensate a che sfiga se una volta trovata la cura ti risvegli in un mondo dove la chioma è passata di moda e la boccia è la nuova evoluzione xd) o ci si deve evolvere verso il distacco da società e giusto comune,divenire eremiti e misantropi sino a liberarsi dell'inutilità dell'altrui giudizio che è sempre e comunque di parte e mirato al proprio tornaconto personale...da una parte c'è una persona che nasce con determinate caratteristiche genetiche (e che in buona fede cerca di migliorarsi facendo sacrifici magari) ,dall'altra ci sono persone sicuramente molto peggiori e con più difetti ma che approfittano della debolezza del soggetto per lucrare e condurre una vita molto agiata (diversi chirurghi famosi della calvizie o derma sono messi maluccio a chioma eh.. ) Serve chiarezza...chi predica il lavoro non ha mai lavorato ,chi si nasconde dietro al titolo ha la libertà di delinquere e lucrare certo di non poter essere perseguito penalmente ,chi sa davvero fare qualcosa spesso e volentieri muore in miseria e screditato da tutti si veda (non me ne vogliate un dr.De Donno vs il re dei salotti in pandemia...manco lo nominò ma è glabro :-(). )
Suzhou, April 18, 2024 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, regrets to announce the unexpected outcome of the Phase 2 clinical trials for its in-house developed first-in-class proteolysis targeting chimera (PROTAC) compound GT20029 in China for the treatment of male androgenetic alopecia (AGA).
Despite promising preclinical data and the completion of enrollment of 180 patients across 12 clinical research centers in China, the Phase 2 clinical trials for GT20029 have concluded with unexpected outcomes. The drug failed to meet the desired efficacy endpoints in treating male AGA patients, as compared to placebo, resulting in an unforeseen setback for the company.
Dr. Youzhi Tong, founder, Chairman, and Chief Executive Officer of Kintor Pharma, expressed his disappointment, stating, “We were optimistic based on the promising results from earlier trials, but unfortunately, the Phase 2 trials did not yield the expected outcome. We remain committed to our mission of developing effective treatments for hair loss and other dermatological conditions, and we will continue to explore other avenues in our research efforts.”
Dr. Tong also addressed the individuals following Kintor for potential solutions to their hair loss, saying, "We understand the anticipation of those who have been following our progress in the development of hair loss treatments. While we share in their disappointment with these results, we urge them to remain patient and resilient. In the meantime, they may wish to perfect their comb over technique while we work diligently to find novel solutions."
The company extends its gratitude to all the principal investigators, clinical research centers, and staff involved in the Phase 2 clinical trials of GT20029 and reaffirms its dedication to bringing innovative therapies to patients worldwide.
A voi.
Despite promising preclinical data and the completion of enrollment of 180 patients across 12 clinical research centers in China, the Phase 2 clinical trials for GT20029 have concluded with unexpected outcomes. The drug failed to meet the desired efficacy endpoints in treating male AGA patients, as compared to placebo, resulting in an unforeseen setback for the company.
Dr. Youzhi Tong, founder, Chairman, and Chief Executive Officer of Kintor Pharma, expressed his disappointment, stating, “We were optimistic based on the promising results from earlier trials, but unfortunately, the Phase 2 trials did not yield the expected outcome. We remain committed to our mission of developing effective treatments for hair loss and other dermatological conditions, and we will continue to explore other avenues in our research efforts.”
Dr. Tong also addressed the individuals following Kintor for potential solutions to their hair loss, saying, "We understand the anticipation of those who have been following our progress in the development of hair loss treatments. While we share in their disappointment with these results, we urge them to remain patient and resilient. In the meantime, they may wish to perfect their comb over technique while we work diligently to find novel solutions."
The company extends its gratitude to all the principal investigators, clinical research centers, and staff involved in the Phase 2 clinical trials of GT20029 and reaffirms its dedication to bringing innovative therapies to patients worldwide.
A voi.
Quindi un allegro buco dell'acqua ?Suzhou, April 18, 2024 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, regrets to announce the unexpected outcome of the Phase 2 clinical trials for its in-house developed first-in-class proteolysis targeting chimera (PROTAC) compound GT20029 in China for the treatment of male androgenetic alopecia (AGA).
Despite promising preclinical data and the completion of enrollment of 180 patients across 12 clinical research centers in China, the Phase 2 clinical trials for GT20029 have concluded with unexpected outcomes. The drug failed to meet the desired efficacy endpoints in treating male AGA patients, as compared to placebo, resulting in an unforeseen setback for the company.
Dr. Youzhi Tong, founder, Chairman, and Chief Executive Officer of Kintor Pharma, expressed his disappointment, stating, “We were optimistic based on the promising results from earlier trials, but unfortunately, the Phase 2 trials did not yield the expected outcome. We remain committed to our mission of developing effective treatments for hair loss and other dermatological conditions, and we will continue to explore other avenues in our research efforts.”
Dr. Tong also addressed the individuals following Kintor for potential solutions to their hair loss, saying, "We understand the anticipation of those who have been following our progress in the development of hair loss treatments. While we share in their disappointment with these results, we urge them to remain patient and resilient. In the meantime, they may wish to perfect their comb over technique while we work diligently to find novel solutions."
The company extends its gratitude to all the principal investigators, clinical research centers, and staff involved in the Phase 2 clinical trials of GT20029 and reaffirms its dedication to bringing innovative therapies to patients worldwide.
A voi.